Usona and Compass file new drug applications for psilocybin depression treatments
Will Usona Institute Have the First FDA Approved Psilocybin Drug?
DoubleBlind reports that the nonprofit Usona Institute reportedly submitted a New Drug ApplicationNDAA new drug application, the formal request asking the FDA to approve a new medicine for sale in the United States.Open the glossary to the FDAFDAThe Food and Drug Administration, the United States regulator of medicines, medical devices and food.Open the glossary on November 2, 2026 for its synthetic psilocybin candidate for major depressive disorder (MDD), a filing first reported by Psychedelic Alpha that Usona declined to comment on.
Key facts
- Compound
- Psilocybin
- Condition
- Depression
- Organisations
- Compass Pathways, Usona Institute
- Regulator
- FDA (United States)
- Source
- DoubleBlind (doubleblindmag.com)
- Published
- Original
- Read it at doubleblindmag.com
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: DoubleBlind · doubleblindmag.com
Connected to
- Compound
- Psilocybin
- Condition
- Depression
- Organisations
- Compass PathwaysUsona Institute
- Regulator
- FDA (United States)